Drugs / hrIL-2
Trials 0
Also used as a comparator or background therapy in 3 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT02467504 Comparator | Jul 2015 → Jan 2017 | rheumatoid arthritis | Peking University People's Hospital | Completed | No outcome recorded |
| Phase 2 | NCT02464319 Comparator | Jun 2015 → Mar 2017 | Sjogren syndrome | Peking University People's Hospital | Completed | No outcome recorded |
| Phase 2 | NCT02465580 Comparator | Jun 2015 → Jun 2017 | systemic lupus erythematosus | Peking University People's Hospital | Unknown | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | hrIL-2 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02465580 ↗ |
| Known as | Human recombinant IL-2 | “Human recombinant IL-2” NCT02467504 ↗ |
| Modality | Protein / enzyme biologic | “human recombinant interleukin-2” NCT02464319 ↗ |
| Route | Subcutaneous | “1 million U doses of human recombinant interleukin-2 s.c. injection” NCT02464319 ↗ |